Skip to main content
. 2011 May 15;14:24. doi: 10.1186/1758-2652-14-24

Table 3.

Proportions with virological failure, non-resistance, and second line switch, by strategy (1000-patient Markov cohort analysis)

Strategy Proportion of cohort with virological failure Proportion of virological failures identified as non-resistant Proportion of cohort switched to second-line therapy
Routine monitoring (RM) 19.8% 0.0% 19.8%
Resistance testing (RT) 20.2% 16.8% 16.7%
Limited testing (LT) 20.2% 11.4% 17.8%